Longevity
The New IP Playbook for Beauty and Longevity: Don’t Patent the Molecule, Patent the System
The longevity industry loves to celebrate discovery. We romanticize the eureka moment in the lab, the new mechanism unearthed, the biomarker that might finally bend the curve of human healthspan. Yet, as investors move from curiosity to disciplined capital allocation, a quiet shift is happening: they are no longer funding discovery alone, they are funding ...
